Merck & Co., Inc. (TSX:MRK)

Market Cap	357.17B
Revenue (ttm)	89.47B
Net Income (ttm)	26.51B
Shares Out	n/a
EPS (ttm)	10.52
PE Ratio	13.47
Forward PE	11.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,945
Average Volume	7,217
Open	22.86
Previous Close	22.81
Day's Range	22.86 - 23.66
52-Week Range	16.84 - 23.95
Beta	n/a
RSI	65.63
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Pharmaceutical Preparations
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD